NEW YORK, February 26 /PRNewswire-FirstCall/ -- SPO Medical Inc. (SPOM)( http://finance.yahoo.com/q?s=SPOM.OB), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced its first commercial shipments of its recently announced professional pulse oximeters; the PulseOx 6000(TM) and PulseOx 6100(TM).
At the end of the fourth quarter 2007, SPO Medical introduced these two new professional products at the 53rd Annual International Respiratory Congress of the American Association for Respiratory Care (AARC) in Orlando, Florida and at the 39th MEDICA World Forum for Medicine in Dusseldorf, Germany.
The PulseOx 6000(TM) (finger device) and PulseOx 6100(TM) (hand-held device) are both designed for medical professionals, hospitals and managed care facilities. Based on SPO Medical’ proprietary patented algorithms, both the PulseOx 6000(TM) and PulseOx 6100(TM) use Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation and heart rate. In addition, these devices utilize the new SPO Medical AutoSpot(TM) technology for accurate measurements even with patients that suffer from low perfusion.
SPO Medical’s focus for these products is the professional medical market. Since the announcement of these new products, an order backlog has been building in the Company’s major markets, the United States and European countries. Within the United States, SPO Medical will be targeting Hospital GPO’s (General Purchasing Organizations) which service thousands of hospital establishments. In addition, the Company will be targeting large medical equipment distributors which service Outpatient Surgery Centers, Integrated Healthcare Delivery Networks and Federal Government facilities.
“Three months ago, we announced the PulseOx 6000(TM) and PulseOx 6100(TM) products; since then, orders have been building in all our major markets,” said Michael Braunold, President and Chief Executive Officer of SPO Medical. “This marks SPO Medical’s first entree into the professional healthcare market, after developing a solid reputation over the last three years in the homecare market. These new products further demonstrate our long-term strategy of adapting SPO Medical’s patented technology platform to new applications, which provide healthcare service providers and consumers with cost-effective life-enhancing information.”
About SPO Medical
SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.
Safe Harbor:
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading “Risk Factors” in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. We undertake no obligation to revise or update any forward-looking statement for any reason.
info@spomedical.comjerry@target3.com
CONTACT: SPO Medical Contact: Michael Braunold, President & CEO,
info@spomedical.com, +1-805-823-8163; Target 3 Communications Contact:
Jerry Cahn, Ph.D., J.D., President, jerry@target3.com, +1-646-827-0009
